Intas Pharmaceuticals Ltd and Henlius Biotech enter into Exclusive License Agreement to commercialise serplulimab - A Novel Anti-PD1 mAb in Europe & India

Oct 28, 2023

Ahmedabad (Gujarat) [India], October 28: Intas Pharmaceuticals Limited ("Intas") has entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) for the...

Intas and Henlius receive positive CHMP opinion for HETRONIFLY® (HANSIZHUANG in China) as first-line treatment for extensive-stage small cell lung cancer

Sep 25, 2024

Ahmedabad (Gujarat) [India], September 25: Intas Pharmaceuticals Limited ("Intas") has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...

Intas Pharmaceuticals Launches HETRONIFLY™ (Serplulimab), India's First Novel Immunotherapy for Advanced Small Cell Lung Cancer

Aug 06, 2025

Ahmedabad (Gujarat) [India], August 6: Intas Pharmaceuticals has launched HETRONIFLY™ (Serplulimab), the first PD-1 inhibitor globally approved for the treatment of Extensive-Stage Small Cell...